

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): Ibopamine maleate salt (1:1).

Claim 2 (Original): Pharmaceutical composition for ophthalmic use, characterized in that it comprises ibopamine maleate (1:1) together with at least one pharmaceutically acceptable vehicle.

Claim 3 (Original): Pharmaceutical composition according to Claim 2, characterized in that it is in the form of an ointment or eyedrops.

Claim 4 (Currently Amended): Pharmaceutical composition according to Claim 2[[or 3]], characterized in that the amount of ibopamine is between 0.01% and 6% by weight.

Claim 5 (Currently Amended): Pharmaceutical composition according to Claim 2[[or 3]], characterized in that the amount of ibopamine is between 0.1% and 5% by weight.

Claim 6 (Original): Process for preparing the ibopamine maleate salt (1:1), characterized in that it includes the addition of maleic acid, dissolved in a suitable organic solvent, to ibopamine base, also dissolved in a suitable organic solvent, in a 1:1 molar ratio.

Claim 7 (Original): Process according to Claim 6, characterized in that the abovementioned addition is performed under an atmosphere of an inert gas.

Claim 8 (Currently Amended): Process according to Claim 6[[or 7]], characterized in that the abovementioned addition is performed at room temperature.

Claim 9 (Currently 'Amended): Process according to ~~any one of the preceding Claims 6 to 8~~ Claim 6, characterized in that the salt formed is isolated via precipitation and filtration.

Claim 10 (Currently Amended): Process according to ~~any one of the preceding Claims 6 to 9~~ Claim 6, characterized in that the abovementioned organic solvent is acetone.

Claim 11 (Original): Process according to Claim 10, characterized in that the salt is precipitated from the acetone solution via addition of ethyl ether.